

Temporal stability of therapeutic microbubbles

Antonios N. Pouliopoulos¹, Daniella A. Jimenez¹, Alexander Frank¹, Alexander Robertson¹, Lin Zhang¹, Alina R. Kline Schoder¹, Vividha Bhaskar¹, Mitra Harpale¹, Elizabeth Caso¹, Nicholas Papananou¹, Rachel Anderson¹, Rachel Li¹, and Elisa E. Konofagou^{1,2}

1. Department of Biomedical Engineering, 2. Department of Radiology, Columbia University, NY, USA

Non-invasive blood-brain barrier (BBB) opening using focused ultrasound (FUS) requires intravenous injection of pre-formed microbubbles. Although microbubble behavior during exposure to imaging sequences has been studied extensively, our understanding of microbubble stability within a therapeutic field is still incomplete. Here, we studied the temporal stability of microbubbles during therapeutic FUS exposure in two timescales: the short time scale (i.e., μ s of low-frequency ultrasound exposure) and the long time scale (i.e., days post-activation). Microbubbles had a concentration decay constant of 0.02 d^{-1} but maintained a stable size distribution for up to 3 weeks ($< 10\%$ variation). Microbubbles flowing through a 4-mm vessel within a tissue-mimicking phantom (5% gelatin) were exposed to therapeutic pulses (f_c : 0.5 MHz, peak-negative pressure: 300 kPa, pulse length: 1 ms, pulse repetition frequency: 1 Hz, $n=10$). We recorded and analyzed the microbubble acoustic emissions with concentration-matched samples (10^7 microbubbles/ml) on day 0, 7, 14, and 21 after activation. Temporal stability decreased while inertial cavitation increased over time both *in vitro* and *in vivo*, possibly due to changes in the lipid shell. BBB opening volume in mice ($n=3$) measured through T₁-weighted contrast-enhanced MRI was equal to $19.1 \pm 7.1 \text{ mm}^3$, $21.8 \pm 14 \text{ mm}^3$, $29.3 \pm 2.5 \text{ mm}^3$, and $38 \pm 20.1 \text{ mm}^3$ on day 0, 7, 14, and 21, respectively, showing no significant difference over time (p-value: 0.49). In conclusion, microbubbles maintain their capacity to produce similar therapeutic effects over a period of 3 weeks after activation, as long as the natural concentration decay is accounted for.




Figure: A) *In vitro* and *in vivo* experimental setup. B) *In vitro* microbubble stability. i) Mean and maximum microbubble size evolution. ii) Microbubble lifetime over time, expressed as the time required for 20% or 80% of the total energy to be emitted (i.e., t_{20} and t_{80}). iii) Normalized spectra over time. iv) Cavitation doses evolution. SCD_h: harmonic stable cavitation dose, SCD_u: ultraharmonic cavitation dose, ICD: inertial cavitation dose. C) *In vivo* microbubble stability. Spectrogram evolution, showing increase of broadband emissions with storage time. D) BBB opening evolution over time.